US Urological Science

Open and Minimally Invasive Radical Cystectomy: How Do They Compare?

Bladder cancer is the ninth most common cancer diagnosis in Australia and the fourth most common among men, and much of its treatment rests on one irreversible decision: how the bladder is removed. For muscle-invasive disease, and for high-risk non-muscle-invasive tumours that recur despite bladder-preserving therapy, radical cystectomy with pelvic lymph node dissection remains the standard operation. What has shifted over the past two decades is not whether the bladder comes out but how the operation is done — through a midline laparotomy, through keyhole ports with laparoscopic instruments, or on a robotic platform offering three-dimensional vision and wristed articulation.

This comparison matters to readers of Urological Science, the Elsevier journal published for the Taiwan Urological Association, whose content spans prostate disorders, lower urinary tract symptoms, kidney stones and bladder cancer alongside open-access research and articles in press. Its editorial information reflects an international readership that wants operative detail rather than headlines. Australian surgeons and patients face additional questions about public hospital access, private coverage, recovery at home and travel from regional centres, and those questions deserve attention alongside the trial data.

Why the technique decision shapes everything downstream

Radical cystectomy is rarely a single act. It involves removing the bladder, dissecting pelvic lymph nodes, and fashioning a urinary diversion — most often an ileal conduit, sometimes a neobladder or ureteric or colonic substitute. Each of those steps carries its own morbidity, and the approach used to accomplish them influences blood loss, wound complications, ileus, length of stay, catheter and stoma care, continence, sexual function and the time a patient is away from work.

The choice also propagates through the health system. Theatre time, consumable costs, intensive care utilisation and readmissions all differ between platforms, and these differences land with payers. In Australia, where public hospital surgery is funded through Medicare and elective procedures in private hospitals are largely covered by private insurers, the capital cost of a robotic system and the cost per case are weighed by hospital boards and by clinicians who refer patients to particular surgeons.

Access is uneven. Robotic cystectomy programmes are now established in Melbourne, Sydney, Brisbane and Adelaide, with most public robotic capacity located in metropolitan teaching hospitals. Patients living in regional and remote areas — Darwin, Townsville, Rockhampton, Bendigo or Kalgoorlie — often travel for staging and surgery and then manage drains, catheters and follow-up surveillance cystoscopies back home, a burden that telehealth follow-up and community nursing services partly offset.

Open radical cystectomy: technique and enduring strengths

Open cystectomy through a midline incision remains the benchmark against which newer methods are judged. It offers speed, tactile feedback, direct exposure for challenging adhesions or locally advanced disease, and an established technique for pelvic lymph node dissection that yields nodal tissue readily comparable with laparoscopic or robotic dissection. It is also the least expensive platform, requiring no capital purchase and minimal disposable instrumentation.

The commonest argument against open surgery is that it causes more morbidity, and the evidence supports some of that: open wounds are more vulnerable to infection, and open patients generally require longer hospital stays and stronger analgesia. Yet the oncological argument has weakened considerably. Trials that have randomised patients to open, laparoscopic or robotic cystectomy report broadly similar rates of positive surgical margins, comparable nodal yields, and recurrence-free survival that does not differ significantly between arms. The 2024 RAMP trial, for instance, found no meaningful difference in two-year recurrence-free survival between robotic and open approaches.

Nor has robotic surgery displaced open surgery entirely. Many units in Australia still favour open cystectomy for patients with prior abdominal surgery, extensive disease, or frailty, and the appeal of a familiar, fast, reproducible operation in a patient who may need a prolonged intensive care stay is difficult to dismiss.

Laparoscopic and robotic approaches in contemporary practice

Laparoscopic cystectomy uses four to five ports, a pneumoperitoneum and steep Trendelenburg positioning, and was the first minimally invasive iteration to generate serious comparative data. Robotic cystectomy refines this further with console-based control, tremor filtration and a learning curve that most units estimate at between 30 and 50 cases before operative times and outcomes plateau.

Randomised evidence has been reassuring rather than revolutionary. The BA06 trial, which randomised 300 patients, found that robotic and open cystectomy produced similar complication rates within 90 days, with operative time longer in the robotic arm. The SHARE trial, comparing robotic and open cystectomy with neobladder diversion, detected no significant difference in quality of life at six or twelve months. Readers who want a broader perspective on operative technique and instrument handling may find an a broader surgical overview useful alongside these studies.

The real drivers of uptake in Australia are workflow and workforce. Robotic platforms are listed with the Therapeutic Goods Administration, and procurement has mostly come through private hospital capital investment with public-private partnerships. Robotic teams can share a single console across two or three urologists, which suits the way Australian private practice is structured — surgeons working in parallel rather than in parallel with technology.

Complications, recovery and the perioperative burden

Blood loss is consistently lower with laparoscopic and robotic approaches, and transfusion requirements fall with it. Against this, prolonged steep Trendelenburg positioning, pneumoperitoneum and longer anaesthetic times bring their own risks, including hypercapnia, ocular complications and thromboembolism. Overall major complication rates nonetheless cluster in the same broad band across techniques, with bowel obstruction, urinary tract infection, wound or port-site problems and venous thromboembolism accounting for most events.

Recovery protocols have mattered as much as the platform. Enhanced recovery pathways in Australian units now emphasise minimal bowel preparation, early oral intake, avoidance of routine drains, opioid-sparing analgesia and structured discharge planning. Those routines have been sharpened by national regulatory attention to opioid prescribing, which has made opioid-free or low-opioid diversion pathways a practical target rather than an aspiration.

The lived experience of recovery deserves weight. A patient returning from cystectomy lives with a catheter, a stoma or intermittent catheterisation, and often a night bag, and Australian households typically manage that with practical habits — pharmacy runs, hardware store trips for supplies, and family members who share the load. Community nursing and stoma services are widely used, and access to continence products varies between state schemes and private insurers, which affects how quickly a patient can resume ordinary life.

Cancer control, functional outcomes and quality of life

Oncologically, the technique has proven remarkably neutral. Margin positivity rates, nodal involvement and pathological stage distribution are similar across open, laparoscopic and robotic operations, and the robotic approach has not delivered a measurable improvement in recurrence-free survival. What it has delivered is a favourable trend in nerve-sparing dissection, with robotic surgeons reporting preservation of erectile function in a higher proportion of sexually active men receiving nerve-sparing cystectomy.

Functional results also converge. Patients with a conduit report high satisfaction and reliable continence, while neobladder patients face a longer adaptation period with daytime voiding, nocturia and catheter use in the early months. Studies comparing platforms have found no significant difference in global quality of life, urinary function or sexual function between robotic and open surgery when diversion is matched, suggesting that diversion type and preoperative fitness explain more than the surgical approach.

Australian data from Victorian, New South Wales and South Australian cohorts mirror the international picture, with patient-reported outcomes improving over the first year and then plateauing. The practical implication is that counselling should focus on the diversion and the patient's baseline function, rather than on the promise that one console produces better continence than another.

Weighing evidence, cost and access in the Australian setting

Practical considerations for surgeons and patients

For surgeons choosing an approach:

For patients and families:

The comparison ultimately favours informed choice over enthusiasm. Randomised data show that minimally invasive techniques achieve oncological and functional outcomes comparable to open surgery, while reducing blood loss and shortening hospital stay for many patients; the persistent differences lie in cost, theatre time, learning curve and access. Surgeons must keep an open mind about which technique suits which patient, and patients should be given the honest numbers rather than the marketing. Those wishing to publish their own work in this field, or to review the current and past issues, abstracts and open-access articles on the journal site, can consult the author guidelines and follow the submission instructions there.